Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to prevent or treat hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** * **Prevention:** 20 mEq (1.5 g) once daily. * **Treatment:** 40-100 mEq (3-7.5 g) per day, divided into 2-5 doses. * **Maximum daily dose:** Generally not to exceed 200 mEq (15 g) per day, but typically much lower doses are used. * **Intravenous (IV):** * **Prevention:** 10-20 mEq (0.75-1.5 g) per day. * **Treatment:** 20-40 mEq (1.5-3 g) per day, may increase up to 100 mEq (7.5 g) per day in severe, symptomatic hypokalemia or if unresponsive to lower doses. * **Concentration:** **Crucial safety point:** IV KCl must be diluted. Concentrations > 40 mEq/L in peripheral IVs and > 20 mEq/L in central IVs are generally not recommended due to phlebitis risk. Higher concentrations (e.g., up to 100 mEq/L) are typically reserved for rapid, emergent correction in critical care settings via central lines and with continuous cardiac monitoring. * **Rate:** **Crucial safety point:** IV infusion rates should not exceed 10-20 mEq/hour (typically ≤ 10 mEq/hr for peripheral lines) unless in a critical care setting with continuous ECG monitoring. Rapid IV administration can be fatal. ## Pediatric Dosing * **Oral:** * **Prevention:** 1-2 mEq/kg/day (maximum 20 mEq/day). * **Treatment:** 2-5 mEq/kg/day (maximum 40 mEq/day), divided into 2-4 doses. * **Intravenous (IV):** * **Prevention:** 0.5-1 mEq/kg/day (maximum 20 mEq/day). * **Treatment:** 1-2 mEq/kg/day (maximum 40 mEq/day), may increase up to 4 mEq/kg/day (maximum 100 mEq/day) in severe cases. * **Concentration and Rate:** Similar dilution and rate restrictions as adults apply, with particular attention to patient size and cardiac status. Concentrations generally should not exceed 10-20 mEq/100 mL and rates should be cautious. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution. Potassium is renally excreted; impaired renal function increases the risk of hyperkalemia. Lower doses and frequent monitoring are essential. ## Contraindications * Hyperkalemia. * Conditions which may predispose to hyperkalemia (e.g., severe renal impairment, untreated Addison's disease, crush syndrome, severe burn injury). * Anuria, oliguria, azotemia. * Gastrointestinal obstruction or delayed gastric emptying (for oral formulations). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain (oral). * **Serious:** Hyperkalemia (muscle weakness, paresthesias, cardiac arrhythmias, cardiac arrest), gastrointestinal ulceration, bleeding, or perforation (especially with sustained-release oral formulations). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride):** Increased risk of hyperkalemia. * **ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan), NSAIDs, Heparin, Trimethoprim:** Can impair potassium excretion, increasing risk of hyperkalemia. * **Aldosterone antagonists (e.g., eplerenone):** Increased risk of hyperkalemia. * **Digitalis glycosides:** Hypokalemia enhances digitalis toxicity. Conversely, hyperkalemia reduces digitalis effect. ## Monitoring * Serum potassium levels (essential). * Renal function (BUN, creatinine). * ECG (especially with IV administration or significant electrolyte imbalances). * Signs and symptoms of hypokalemia and hyperkalemia. ## Clinical Pearls * Oral potassium chloride can be irritating to the GI tract. Use liquid preparations or sprinkle capsules, and advise patients to take with food or a large glass of water to minimize irritation. * Sustained-release formulations have a higher risk of GI ulceration and should be used cautiously, especially in patients with known GI issues. * **IV KCl must be administered with extreme caution.** Errors in preparation or administration can be fatal. Double-check concentrations and infusion rates. Continuous cardiac monitoring is crucial for rapid IV infusions. * Hypokalemia can be exacerbated by certain medications (e.g., diuretics, corticosteroids, beta-agonists) and conditions (e.g., vomiting, diarrhea, inadequate intake). *** *This information is intended for healthcare professionals. Always verify current prescribing information with the official drug monograph or other reliable sources before making clinical decisions.*